LITS — Lite Strategy, Inc.
$0.85
$-0.06 (-6.64%)
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset.
Market Cap
$25.30M
Forward P/E
N/A
52-Week Range
N/A
LITS Price History
Revenue vs. Net Income
$65.3M
Revenue · FY2024
Annual. Net margin is shown under each year.
Free Cash Flow
-$50.5M
FCF · FY2024
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
77.0%
ROCE · FY2024
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
5.0x
Assets ÷ liabilities · FY2024
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.0%
CapEx · FY2024
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.0%
Net buyback · FY2024
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
